Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 10, 2018. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide corporate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: Approximately £14.749 per share.
- Transaction Volume: Ranged from 16 to 18 shares per individual executive.
- Transaction Date: October 9, 2018.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It strictly documents routine equity compensation acquisitions by senior management.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is a regulatory disclosure of insider trading activity compliant with the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total number of shares acquired by all PDMRs on October 9, 2018, to assess aggregate insider buying activity.
- Confirm the market price of GSK ordinary shares on October 9, 2018, to validate the transaction price of £14.749.
- Review the Company's Share Reward Plan terms to understand the structure of partnership and matching shares.
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.